Ganymed Pharmaceuticals
About:
Ganymed Pharmaceuticals is a biopharmaceutical developing therapeutic drugs designed to kill tumor cells without harming healthy tissues.
Website: http://www.ganymed.ag/
Top Investors: VI Partners, Nextech Invest, Landesbank Baden Wurttemberg, Future Capital, MIG Capital
Description:
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
$213M
$1M to $10M
Mainz, Rheinland-Pfalz, Germany
2001-01-01
info(AT)ganymed.ag
Christoph Huber, Dirk Sebastian
11-50
2013-11-18
Private
© 2025 bioDAO.ai